Founded in 2004, Omega Funds is a leading international venture capital firm dedicated to creating and investing in life sciences companies that address the world's most pressing medical needs. The firm focuses on delivering impactful medicines to patients by investing in exceptional founders and entrepreneurs across various therapeutic areas, including oncology, immunology, rare diseases, and precision medicine. Omega Funds employs a stage-agnostic investment approach, engaging in company creation, early venture rounds, late-stage public financing, and direct secondary transactions.

Since its inception, the firm has raised over $2 billion and has been instrumental in bringing 46 products to market, contributing to 39 successful public listings and 35 exits via mergers and acquisitions.